We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Advancing Drug Development in Idiopathic Pulmonary Fibrosis: Tomorrow Is Now.
- Authors
Khor, Yet H.; Ryerson, Christopher J.
- Abstract
The article offers information on the failure of the phase III STARSCAPE trial, which studied recombinant human pentraxin-2, zinpentraxin alfa, in 664 patients with idiopathic pulmonary fibrosis (IPF). Topics include the trial's early termination due to futility, lack of benefit of zinpentraxin alfa compared to placebo on lung function and other outcomes, and the challenges in translating successful phase II trials to phase III trials in IPF.
- Subjects
DRUG development; IDIOPATHIC pulmonary fibrosis; INTERSTITIAL lung diseases; DRUG discovery; PULMONARY fibrosis
- Publication
American Journal of Respiratory & Critical Care Medicine, 2024, Vol 209, Issue 9, p1060
- ISSN
1073-449X
- Publication type
Article
- DOI
10.1164/rccm.202402-0381ED